BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Earnings

  Bayer Touts ‘Modest’ Q2 Performance Amid Sweeping Reorganization

  Bayer’s surprising growth in the second quarter was driven in large part by two pharma products: the prostate cancer drug Nubeqa and the chronic kidney disease treatment Kerendia.

  August 6, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

  August 6, 2024

   · 

  6 min read
• Business

  Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

  August 6, 2024

   · 

  4 min read
• Drug Development

  epres™ Announces Successful Completion of Clinical Studies for Bond Repair Treatment

  August 6, 2024

   · 

  2 min read
• Press Releases

  Parkinson’s Foundation Awards Grants in 40 States for Parkinson’s Community Programs

  August 6, 2024

   · 

  3 min read
• Press Releases

  Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities

  August 6, 2024

   · 

  10 min read
• Press Releases

  SINTX Technologies Announces Appointment of Eric K. Olson as Chief Executive Officer

  August 6, 2024

   · 

  3 min read
• Press Releases

  Gold Rush 2.0: Britannia Mining and Paragon Geochemical Bring Cutting-Edge Assaying Technology to the West Coast

  August 6, 2024

   · 

  3 min read
• 

  Deals

  Daiichi Pays Merck $170M for T-Cell Engager, Expands ADC Partnership

  After dropping $4 billion on a deal with the Japanese company last year, Merck is getting back some of its investment as Daiichi Sankyo buys into a Phase I/II T-cell engager therapy acquired from Harpoon Therapeutics.

  August 6, 2024

   · 

  1 min read

   · 

  Kate Goodwin
• 

  Deals

  Cash-Strapped Sangamo Gets Lifeline from Genentech in Potential $1.9B Neuro Deal

  Sangamo Therapeutics announced Tuesday it secured an exclusive licensing agreement with Roche’s Genentech, which is paying $50 million in near-term upfront fees and milestone payments to develop novel genomic medicines for neurodegenerative diseases.

  August 6, 2024

   · 

  2 min read

   · 

  Tyler Patchen